Lugano, Switzerland, 28 April 2021 – The 2021 ESMO Breast Cancer Congress will be held as a virtual meeting, on 5-8 May.
- Impact of ethnicity-based differences
- Optimising the management of premenopausal women with early breast cancer
- Latest advances in adjuvant, neoadjuvant and immunotherapy
- Cutting-edge surgical research, keynote lecture by Masakazu Toi, Saturday 8 May at 14:15 CEST
The programme will address other topics such as integrating insights from translational research into cancer care: new agents on the horizon; the role of molecular and functional diagnostics as well as biomarkers for more precise treatment options; latest research applications in the clinical setting.
The results of nearly 200 studies from researchers in various parts of the world will be presented either as oral or poster presentations, and published online as a supplement of Annals of Oncology. The abstract titles can be viewed through the online programme.
- “The switch of breast tumours to HER2-low status in recurrence might provide greater therapeutic options”. The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
- “Personalisation of follow-up care is needed to address varying health burdens in breast cancer patients”. As breast cancer becomes a largely curable disease, with more than 70% of women surviving at least 10 years after diagnosis across most of Europe thanks to early detection and treatment, the quality of life after cancer has become an important aspect of the patient journey – one that may be inadequately addressed with current standards of follow-up.
ESMO Breast Cancer Award keynote lectures
Andrew Tutt, The Institute of Cancer Research and Guy’s Hospital, Kings College London, London, UK, will be recognised with the ESMO Breast Cancer Award 2021 for his exceptional contribution to developing our understanding of breast cancer. He will deliver the award keynote lecture “Targeting HR deficiency: Finding an Achilles heel in hereditary breast cancer” on Friday, 7 May at 11:55 CEST.
Also, the congress will host the award lecture of the 2020 recipient of the ESMO Breast Cancer Award, Sherene Loi, Peter MacCallum Cancer Center Melbourne and University of Melbourne, Melbourne, Australia on “Stories in breast cancer immunology and genomics” on Saturday 8 May at 12:00 CEST.
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Only through the official accreditation process with the media registration form, accredited media representatives will be able to access scientific and educational sessions (live streamed and on-demand), live chat and Q&A, e-posters and chat with poster presenters, virtual exhibition and industry satellite symposia, Congress webcasts, and embargoed material.
For further information
ESMO Press Office